Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $24.8 million.

  • Lyell Immunopharma's Net Cash Flow rose 174.79% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 113.22%. This contributed to the annual value of -$38.6 million for FY2024, which is 274.88% down from last year.
  • Lyell Immunopharma's Net Cash Flow amounted to $24.8 million in Q3 2025, which was up 214.54% from -$21.6 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Net Cash Flow high stood at $320.1 million for Q2 2021, and its period low was -$170.9 million during Q3 2021.
  • In the last 3 years, Lyell Immunopharma's Net Cash Flow had a median value of $6.7 million in 2024 and averaged $120,545.
  • Over the last 5 years, Lyell Immunopharma's Net Cash Flow had its largest YoY gain of 781.89% in 2023, and its largest YoY loss of 2,040.45% in 2023.
  • Lyell Immunopharma's Net Cash Flow (Quarterly) stood at -$99.7 million in 2021, then surged by 107.27% to $7.2 million in 2022, then crashed by 2,040.45% to -$140.6 million in 2023, then skyrocketed by 104.77% to $6.7 million in 2024, then spiked by 174.79% to $24.8 million in 2025.
  • Its Net Cash Flow stands at $24.8 million for Q3 2025, versus -$21.6 million for Q2 2025 and $14.7 million for Q1 2025.